Reducing Treatment Burden in IBD with At-Home Therapy Options
Jean-Frederic Colombel, MD, provides a comprehensive overview of subcutaneous infliximab-dyyb injection for ulcerative colitis and Crohn's disease, analyzing clinical trial data, , discussing patient selection for this therapy, and evaluating its place in the evolving inflammatory bowel disease treatment landscape.
EP. 2: Efficacy and Safety of Subcutaneous Infliximab
August 7th 2024A key opinion leader analyzes the clinical remission and endoscopic response data from the LIBERTY CD and LIBERTY UC trials for subcutaneous infliximab-dyyb injection, contrasts it with intravenous infliximab, and evaluates the drug's safety and efficacy profile.
EP. 3: Patient Selection and Switching Patients to Subcutaneous Infliximab
August 7th 2024Jean-Frederic Colombel, MD, examines considerations for transitioning patients from intravenous to subcutaneous infliximab and evaluates the role of subcutaneous infliximab within the evolving landscape of inflammatory bowel disease treatments.
